Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 131


Targeting Epidermal Growth Factor Receptor (EGFR) and Human Epidermal Growth Factor Receptor 2 (HER2) Expressing Bladder Cancer Using Combination Photoimmunotherapy (PIT).

Siddiqui MR, Railkar R, Sanford T, Crooks DR, Eckhaus MA, Haines D, Choyke PL, Kobayashi H, Agarwal PK.

Sci Rep. 2019 Feb 14;9(1):2084. doi: 10.1038/s41598-019-38575-x.


[Near Infrared Photoimmunotherapy for Cancer].

Kobayashi H.

Gan To Kagaku Ryoho. 2019 Jan;46(1):28-33. Japanese.


Host Immunity Following Near-Infrared Photoimmunotherapy Is Enhanced with PD-1 Checkpoint Blockade to Eradicate Established Antigenic Tumors.

Nagaya T, Friedman J, Maruoka Y, Ogata F, Okuyama S, Clavijo PE, Choyke PL, Allen C, Kobayashi H.

Cancer Immunol Res. 2019 Mar;7(3):401-413. doi: 10.1158/2326-6066.CIR-18-0546. Epub 2019 Jan 25.


Photoinduced Ligand Release from a Silicon Phthalocyanine Dye Conjugated with Monoclonal Antibodies: A Mechanism of Cancer Cell Cytotoxicity after Near-Infrared Photoimmunotherapy.

Sato K, Ando K, Okuyama S, Moriguchi S, Ogura T, Totoki S, Hanaoka H, Nagaya T, Kokawa R, Takakura H, Nishimura M, Hasegawa Y, Choyke PL, Ogawa M, Kobayashi H.

ACS Cent Sci. 2018 Nov 28;4(11):1559-1569. doi: 10.1021/acscentsci.8b00565. Epub 2018 Nov 6.


Pitfalls on sample preparation for ex vivo imaging of resected cancer tissue using enzyme-activatable fluorescent probes.

Mochida A, Ogata F, Maruoka Y, Nagaya T, Okada R, Inagaki F, Fujimura D, Choyke PL, Kobayashi H.

Oncotarget. 2018 Nov 13;9(89):36039-36047. doi: 10.18632/oncotarget.26320. eCollection 2018 Nov 13.


Activatable Near-Infrared Fluorescence Imaging Using PEGylated Bacteriochlorin-Based Chlorin and BODIPY-Dyads as Probes for Detecting Cancer.

Ogata F, Nagaya T, Maruoka Y, Akhigbe J, Meares A, Lucero MY, Satraitis A, Fujimura D, Okada R, Inagaki F, Choyke PL, Ptaszek M, Kobayashi H.

Bioconjug Chem. 2019 Jan 16;30(1):169-183. doi: 10.1021/acs.bioconjchem.8b00820. Epub 2018 Dec 14.


Near infrared photoimmunotherapy using a fiber optic diffuser for treating peritoneal gastric cancer dissemination.

Nagaya T, Okuyama S, Ogata F, Maruoka Y, Choyke PL, Kobayashi H.

Gastric Cancer. 2019 May;22(3):463-472. doi: 10.1007/s10120-018-0871-5. Epub 2018 Aug 31.


Near infrared photoimmunotherapy targeting bladder cancer with a canine anti-epidermal growth factor receptor (EGFR) antibody.

Nagaya T, Okuyama S, Ogata F, Maruoka Y, Knapp DW, Karagiannis SN, Fazekas-Singer J, Choyke PL, LeBlanc AK, Jensen-Jarolim E, Kobayashi H.

Oncotarget. 2018 Apr 10;9(27):19026-19038. doi: 10.18632/oncotarget.24876. eCollection 2018 Apr 10.


Endoscopic near infrared photoimmunotherapy using a fiber optic diffuser for peritoneal dissemination of gastric cancer.

Nagaya T, Okuyama S, Ogata F, Maruoka Y, Choyke PL, Kobayashi H.

Cancer Sci. 2018 Jun;109(6):1902-1908. doi: 10.1111/cas.13621. Epub 2018 May 29.


Interstitial near-infrared photoimmunotherapy: effective treatment areas and light doses needed for use with fiber optic diffusers.

Okuyama S, Nagaya T, Sato K, Ogata F, Maruoka Y, Choyke PL, Kobayashi H.

Oncotarget. 2018 Jan 27;9(13):11159-11169. doi: 10.18632/oncotarget.24329. eCollection 2018 Feb 16.


Near Infrared Photoimmunotherapy with Combined Exposure of External and Interstitial Light Sources.

Maruoka Y, Nagaya T, Sato K, Ogata F, Okuyama S, Choyke PL, Kobayashi H.

Mol Pharm. 2018 Sep 4;15(9):3634-3641. doi: 10.1021/acs.molpharmaceut.8b00002. Epub 2018 Feb 21.


Avoiding thermal injury during near-infrared photoimmunotherapy (NIR-PIT): the importance of NIR light power density.

Okuyama S, Nagaya T, Ogata F, Maruoka Y, Sato K, Nakamura Y, Choyke PL, Kobayashi H.

Oncotarget. 2017 Aug 11;8(68):113194-113201. doi: 10.18632/oncotarget.20179. eCollection 2017 Dec 22.


Fluorescence-Guided Surgery.

Nagaya T, Nakamura YA, Choyke PL, Kobayashi H.

Front Oncol. 2017 Dec 22;7:314. doi: 10.3389/fonc.2017.00314. eCollection 2017. Review.


Dynamic changes in the cell membrane on three dimensional low coherent quantitative phase microscopy (3D LC-QPM) after treatment with the near infrared photoimmunotherapy.

Ogata F, Nagaya T, Okuyama S, Maruoka Y, Choyke PL, Yamauchi T, Kobayashi H.

Oncotarget. 2017 Nov 1;8(61):104295-104302. doi: 10.18632/oncotarget.22223. eCollection 2017 Nov 28.


Molecularly Targeted Cancer Combination Therapy with Near-Infrared Photoimmunotherapy and Near-Infrared Photorelease with Duocarmycin-Antibody Conjugate.

Nagaya T, Gorka AP, Nani RR, Okuyama S, Ogata F, Maruoka Y, Choyke PL, Schnermann MJ, Kobayashi H.

Mol Cancer Ther. 2018 Mar;17(3):661-670. doi: 10.1158/1535-7163.MCT-17-0851. Epub 2017 Dec 13.


Characteristics of ovarian cancer detection by a near-infrared fluorescent probe activated by human NAD(P)H: quinone oxidoreductase isozyme 1 (hNQO1).

Nakamura Y, Shen Z, Harada T, Nagaya T, Sato K, Okuyama S, Ogata F, Choyke PL, McCarley RL, Kobayashi H.

Oncotarget. 2017 May 20;8(37):61181-61192. doi: 10.18632/oncotarget.18044. eCollection 2017 Sep 22.


Syngeneic Mouse Models of Oral Cancer Are Effectively Targeted by Anti-CD44-Based NIR-PIT.

Nagaya T, Nakamura Y, Okuyama S, Ogata F, Maruoka Y, Choyke PL, Allen C, Kobayashi H.

Mol Cancer Res. 2017 Dec;15(12):1667-1677. doi: 10.1158/1541-7786.MCR-17-0333. Epub 2017 Sep 18.


Raltegravir blocks the infectivity of red-fluorescent-protein (mCherry)-labeled HIV-1JR-FL in the setting of post-exposure prophylaxis in NOD/SCID/Jak3-/- mice transplanted with human PBMCs.

Ogata-Aoki H, Higashi-Kuwata N, Hattori SI, Hayashi H, Danish M, Aoki M, Shiotsu C, Hashiguchi Y, Hamada A, Kobayashi H, Ihn H, Okada S, Mitsuya H.

Antiviral Res. 2018 Jan;149:78-88. doi: 10.1016/j.antiviral.2017.09.003. Epub 2017 Sep 8.


A topically-sprayable, activatable fluorescent and retaining probe, SPiDER-╬▓Gal for detecting cancer: Advantages of anchoring to cellular proteins after activation.

Nakamura Y, Mochida A, Nagaya T, Okuyama S, Ogata F, Choyke PL, Kobayashi H.

Oncotarget. 2017 Jun 13;8(24):39512-39521. doi: 10.18632/oncotarget.17080.


Near-infrared photoimmunotherapy: a comparison of light dosing schedules.

Ogata F, Nagaya T, Nakamura Y, Sato K, Okuyama S, Maruoka Y, Choyke PL, Kobayashi H.

Oncotarget. 2017 May 23;8(21):35069-35075. doi: 10.18632/oncotarget.17047.

Supplemental Content

Loading ...
Support Center